Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22931042 | 0.95 | ADORA1 (0.49) | ADORA1ADORA3ADORA2AADORA2BPOLB | |
| SCHEMBL19657010 | 0.94 | ADORA1 (0.48) | ADORA1ADORA3ADORA2AADORA2BPOLB | |
| SCHEMBL19657007 | 0.94 | ADORA1 (0.48) | ADORA1ADORA3ADORA2AADORA2BPOLB | |
| SCHEMBL312409 | 0.85 | SLC18A3 (0.50) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL4670822 | 0.85 | ADORA3 (0.40) | ADORA1ADORA3ADORA2AADORA2BNPC1 | |
| Hydrochloric Acid SCHEMBL1653372 | 0.84 | SLC18A3 (0.49) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL8016614 | 0.84 | KDM4E (0.44) | ADORA1ADORA3ADORA2AADORA2BNPC1 | |
| Hydrochloric Acid SCHEMBL311386 | 0.84 | SLC18A3 (0.49) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL6166041 | 0.83 | SLC18A3 (0.47) | ADORA1ADORA3ADORA2B | |
| Hydrochloric Acid SCHEMBL6806273 | 0.81 | SLC18A3 (0.46) | ADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653125-B2 | Cyclohexane derivative having NPY Y5 receptor antagonism | SHIONOGI CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| EP-2404896-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | Shionogi&Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| EP-1306085-B1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1306085-B1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7034034-B2 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-7034034-B2 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-7034034-B2 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2003104255-A3 | SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y5 RECEPTOR | NEUROGEN CORP (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003104255-A2 | SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES | NEUROGEN CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104255-A2 | SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES | NEUROGEN CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION | 2003-07-31 | — | — | US | disclosed |
| JP-2003137872-A | SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVE | NEUROGEN CORP | 2003-05-14 | — | — | JP | disclosed |
| EP-1306085-A1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | Neurogen Corporation (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1306085-A1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | Neurogen Corporation (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1306085-A1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | Neurogen Corporation (US) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | ADORA1 576/4885ADORA3 604/4885ADORA2A 1128/4885 |
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NPY5R, NPY4R, NPY1R | ADORA1 1807/4885ADORA3 1040/4885ADORA2A 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.